Lv4
420 积分 2024-07-01 加入
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
1个月前
已完结
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis
1个月前
已完结
Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulations
1个月前
已完结
SNAC for Enhanced Oral Bioavailability: An Updated Review
1个月前
已完结
797-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants—A Phase 1 Study
2个月前
已完结
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
4个月前
已完结
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
4个月前
已完结
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
4个月前
已完结
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease
4个月前
已完结
P62 Efficacy and safety of picankibart in moderate-to-severe plaque psoriasis: a randomized, double-blind, Phase 3 CLEAR-1 trial
5个月前
已完结
皖公网安备34019202002308
